Diet, physical activity and an adequate escalation of the classical medications (metformin, sulfonylureas and insulin) are the cornerstone of management of an ample majority of patients with type 2 diabetes. The objective of control should be individualized and the patients stage of the disease and present complications should be taken into account. New agents present attractive action mechanisms and characteristics, but there are still a lot of unanswered questions with regard to their efficacy in reducing morbi-mortality, their safety and their combination with other hypoglycemic agents.